Drug intelligence / Profile preview

ATLX-XXXX

Development stage: Preclinical
Lead developer: Alchemab Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

ATLX-XXXX is a preclinical-stage monoclonal antibody being developed by Alchemab Therapeutics for the treatment of chronic kidney disease (CKD). The therapeutic is designed to function as a receptor agonist, targeting a currently undisclosed biological pathway identified through Alchemab's proprietary platform. This platform discovers naturally occurring protective antibodies from "resilient" individuals—those who remain healthy despite a high risk of disease. The program aims to leverage these protective mechanisms to provide renal protection or repair. Alchemab Therapeutics has set a target for an Investigational New Drug (IND) application filing for ATLX-XXXX in the first half of 2027.

Beyond the preview

Go deeper on ATLX-XXXX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATLX-XXXX.

Explore the full profile